TELETRADER News
7/12, 10:24 PM (Source: TeleTrader)
more TeleTrader news

J&J: Risk of developing GBS from vaccine very low

Johnson & Johnson said on Monday that the risk of developing Guillain-Barree syndrome (GBS) after receiving the company's coronavirus vaccine is "very low and the rate of reported cases exceeds the background rate by a small degree."

The company also announced that it has been discussing the issue with the US Food and Drug Administration (FDA) and other health regulators and has shared all reports of adverse matters with relevant authorities. "We strongly support raising awareness of the signs and symptoms of rare events to ensure they can be quickly identified and effectively treated," J&J said in a statement, adding that its shot has been proven to prevent hospitalizations and deaths from COVID-19.

Earlier, it was reported that the FDA will add a new warning label on J&J's COVID vaccine.

Breaking the News / JC